Across TCGA pan-cancer cohorts, TRPV4 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRPV4 data layer compared with 23 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TRPV4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TRPV4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.
CCRCC, PDAC, and LUAD are the cancer types where TRPV4 mass-spec protein most reproducibly stratifies survival.